S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Moldova signs new energy deal that could ease blackout risk
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
OPEC keeps oil targets amid uncertainty on Russian sanctions
FDA change ushers in cheaper, easier-to-get hearing aids
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Moldova signs new energy deal that could ease blackout risk
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
OPEC keeps oil targets amid uncertainty on Russian sanctions
FDA change ushers in cheaper, easier-to-get hearing aids
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Moldova signs new energy deal that could ease blackout risk
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
OPEC keeps oil targets amid uncertainty on Russian sanctions
FDA change ushers in cheaper, easier-to-get hearing aids
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Moldova signs new energy deal that could ease blackout risk
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
OPEC keeps oil targets amid uncertainty on Russian sanctions
FDA change ushers in cheaper, easier-to-get hearing aids
NASDAQ:SRRK

Scholar Rock - SRRK Stock Forecast, Price & News

$7.87
0.00 (0.00%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$7.27
$8.03
50-Day Range
$6.52
$9.76
52-Week Range
$4.32
$28.08
Volume
124,491 shs
Average Volume
194,167 shs
Market Capitalization
$406.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.00

Scholar Rock MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
230.4% Upside
$26.00 Price Target
Short Interest
Bearish
5.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$1.29 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.76 out of 5 stars

Medical Sector

848th out of 1,034 stocks

Biological Products, Except Diagnostic Industry

141st out of 171 stocks

SRRK stock logo

About Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Receive SRRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

SRRK Stock News Headlines

H.C. Wainwright Keeps Their Buy Rating on Scholar Rock Holding (SRRK)
Jay Backstrom is the new CEO at Scholar Rock
Expert Ratings for Scholar Rock Holding
See More Headlines
Receive SRRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

SRRK Company Calendar

Last Earnings
11/08/2021
Today
12/04/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/06/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRRK
Employees
145
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.00
High Stock Price Forecast
$33.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+230.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-131,800,000.00
Net Margins
-236.95%
Pretax Margin
-352.19%

Debt

Sales & Book Value

Annual Sales
$18.82 million
Book Value
$5.68 per share

Miscellaneous

Free Float
50,604,000
Market Cap
$406.56 million
Optionable
Not Optionable
Beta
0.72

Key Executives

  • Mr. Edward H. Myles M.B.A.Mr. Edward H. Myles M.B.A. (Age 50)
    MBA, CFO, COO & Treasurer
    Comp: $615.87k
  • Dr. Jay T. Backstrom M.D. (Age 67)
    M.P.H., Pres, CEO & Director
  • Ms. Catherine Hu
    VP of Investor Relations & Corp. Communications
  • Ms. Junlin Ho J.D. (Age 43)
    Gen. Counsel & Corp. Sec.
  • Ms. Caryn Parlavecchio (Age 50)
    Chief HR Officer
  • Ms. Lisa Amaya Price
    Sr. VP of HR
  • Dr. George G. Nomikos M.D.
    Ph.D., Sr. VP of Medical & Clinical Sciences and Head of Muscle Therapeutic Area
  • Ms. Erin Moore (Age 47)
    Sr. VP of Fin.
  • Mr. Ryan Iarrobino
    Sr. VP of Clinical Devel. & Operations













SRRK Stock - Frequently Asked Questions

Should I buy or sell Scholar Rock stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SRRK shares.
View SRRK analyst ratings
or view top-rated stocks.

What is Scholar Rock's stock price forecast for 2023?

6 brokerages have issued 1 year price targets for Scholar Rock's stock. Their SRRK share price forecasts range from $19.00 to $33.00. On average, they predict the company's share price to reach $26.00 in the next twelve months. This suggests a possible upside of 230.4% from the stock's current price.
View analysts price targets for SRRK
or view top-rated stocks among Wall Street analysts.

How have SRRK shares performed in 2022?

Scholar Rock's stock was trading at $24.84 at the beginning of the year. Since then, SRRK shares have decreased by 68.3% and is now trading at $7.87.
View the best growth stocks for 2022 here
.

When is Scholar Rock's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023.
View our SRRK earnings forecast
.

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Co. (NASDAQ:SRRK) issued its earnings results on Monday, November, 8th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.85) by $0.17. The company had revenue of $5.46 million for the quarter, compared to analysts' expectations of $4.65 million. Scholar Rock had a negative trailing twelve-month return on equity of 54.30% and a negative net margin of 236.95%. The business's revenue for the quarter was up 79.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.79) earnings per share.

What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

When did Scholar Rock IPO?

(SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Scholar Rock's stock symbol?

Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."

Who are Scholar Rock's major shareholders?

Scholar Rock's stock is owned by a number of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (19.57%), Vanguard Group Inc. (5.34%), BlackRock Inc. (3.72%), Laurion Capital Management LP (1.57%), State Street Corp (0.88%) and Citadel Advisors LLC (0.86%). Insiders that own company stock include Amir Nashat, Edward H Myles, Gregory John Carven, Jeffrey S Flier, Michael Gilman and Public Equities LP Invus.
View institutional ownership trends
.

How do I buy shares of Scholar Rock?

Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Scholar Rock's stock price today?

One share of SRRK stock can currently be purchased for approximately $7.87.

How much money does Scholar Rock make?

Scholar Rock (NASDAQ:SRRK) has a market capitalization of $406.56 million and generates $18.82 million in revenue each year. The company earns $-131,800,000.00 in net income (profit) each year or ($2.79) on an earnings per share basis.

How many employees does Scholar Rock have?

The company employs 145 workers across the globe.

How can I contact Scholar Rock?

Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.scholarrock.com. The company can be reached via phone at (857) 259-3860, via email at chu@scholarrock.com, or via fax at 866-493-4935.

This page (NASDAQ:SRRK) was last updated on 12/4/2022 by MarketBeat.com Staff